CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 25 enrolled
Drug / intervention
Gemini SCS neuromodulation systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05590000
NCT05590000N/ACompleted
CompareCT.gov

Study of Gemini Rechargeable Spinal Cord Stimulation System

Abbott Medical Devices·interventional·Posted Oct 21, 2022·Updated Oct 24, 2023

In Brief

A clinical study evaluating Gemini SCS neuromodulation system for Chronic Pain. Completed, enrolled 25 participants across 6 sites.

Detailed Summary

The aim of this pre-market, prospective, single-arm, non-randomized, open-label, multi-center clinical study is to collect confirmatory data to show that the Gemini SCS neurostimulation system functions as intended in a clinical setting.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Pain
CountriesAustralia
Collaborators--

Timeline

N/ACompletedFinished
2023202420252026
First PostedOct 21, 2022
Enrollment StartSep 20, 2022
Primary CompletionJan 19, 2023
Study CompletionFeb 17, 2023
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 3.7 years ago

Interventions

Gemini SCS neuromodulation systemdevice

This neurostimulation system is indicated as an aid in the management of chronic, intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back and leg pain, angina pectoris and peripheral vascular disease.